Epirubicin micelle formulation - NanoCarrier/Kowa

Drug Profile

Epirubicin micelle formulation - NanoCarrier/Kowa

Alternative Names: K-912; NC 6003; NC-6300

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoCarrier
  • Developer Kowa; NanoCarrier
  • Class Cytostatic antibiotics; Doxorubicins
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV)
  • 19 Jul 2017 Epirubicin micelle formulation - NanoCarrier/Kowa receives Orphan Drug status for Soft tissue sarcoma in USA (NanoCarrier pipeline, October 2017)
  • 30 Jun 2017 Phase-I/II clinical trials in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT03168061)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top